By proceeding, you agree to our Terms of Use and Privacy Policy.
Over the past 11 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the next wave of biotherapeutics, advances in technologies, and the valuable exchange of high-quality research from all disciplines of immuno-oncology. CHI’s IO Summit provides access to a comprehensive 3-day program for participants to evaluate bi- or multi-specific biotherapeutics, explore the latest developments in existing and emerging cellular therapies, develop predictive preclinical models for translational strategies, appraise AI and computational tools for the discovery of new targets, target classes, and combinations to overcome resistance. Every year, we assemble an international mix of thought-leaders and decision-makers from industry and academia to bring you the latest developments in immuno-oncology, so that, together, we continue to align as a formidable force against cancer. Additionally, the progressive venue provides extensive networking and collaborative opportunities to enable teams to focus on their goals as they advance our understanding of the immune system to provide next-generation immunotherapies to all patients.
Upgrade yourself with the leading edge immuno-oncology advancements.
Explore emerging technologies for IO targeting & discovery, bispecific antibodies for cancer immunotherapy, advances in CAR T therapy and more.
Leverage extensive networking and collaborative opportunities to advance your goal of providing next-generation immunotherapies to all patients.
Leave the summit empowered to make a difference in the fight against cancer. Gain inspiring insights & connections to improve cancer immunotherapy.
At a FutureCon Conference, you’ll receive high-level cyber security training, and learn cutting-edge security approaches to manage risks in the constantly evolving world of cyber threats.
At Charles River, we are passionate about our role in improving the quality of people’s lives.
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific.
Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity’s greatest challenges.
The OmniAb discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.
About FUJIFILM Pharmaceuticals U.S.A., Inc.Our mission is to deliver innovative drugs to the broader population of patients worldwide at reasonable cost.FUJIFILM Pharmaceuticals U.S.A., Inc. started its operation in 2008 as FUJIFILMs global center fo
About FUJIFILM Pharmaceuticals U.S.A., Inc.Our mission is to deliver innovative drugs to the broader population of patients worldwide at reasonable cost.FUJIFILM Pharmaceuticals U.S.A., Inc. started its operation in 2008 as FUJIFILMs global center for new drug development. Today we are conducting mu
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.